External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

AGW 2026

-
Coming soon
09:00 AM
Duration 90mins Perth, Australia
Symptomatic remission and health-related quality of life with afimkibart treatment for moderately to severely active ulcerative colitis in the Phase IIb TUSCANY-2 trial
Rupert W. Leong, Andres Yarur, Jessica R. Allegretti, Silvio Danese, Laurent Peyrin-Biroulet, Daniela Bojic, Karen Lasch, Courtney Schiffman, Jinglan Pei, Anindita Banerjee, Deepa E. Chandra, Elena Peeva, Srividya Neelakantan, Michael S. Vincent, Vipul Jairath

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar